A humanized antibody against human cytomegalovirus (CMV) gpUL75 (gH) for prophylaxis or treatment of CMV infections.
A humanized monoclonal antibody that binds to the 86-kDa glycoprotein, gpUL75 (gH), of human cytomegalovirus (CMV) has been developed. The six complementarity determining regions of the heavy and light chains of the mouse antibody HCMV16 were transferred to human antibody framework sequences and combined with human antibody constant regions to produce a complete antibody. The reshaped antibody recognized cells infected with a variety of virus strains and neutralized clinical isolates of CMV as efficiently as laboratory strains in a conventional plaque reduction assay. This antibody provides a potential agent for the prevention or treatment of CMV infections in humans.
Hamilton
A A
AA
Scotgen Biopharmaceuticals Inc., Aberdeen Science and Technology Park, United Kingdom.
Manuel
D M
DM
Grundy
J E
JE
Turner
A J
AJ
King
S I
SI
Adair
J R
JR
White
P
P
Carr
F J
FJ
Harris
W J
WJ
D000595:Amino Acid Sequence; D000818:Animals; D000914:Antibodies, Viral / Q000737:chemistry / Q000276:immunology*; D001483:Base Sequence; D002460:Cell Line; D003586:Cytomegalovirus Infections / Q000188:drug therapy / Q000517:prevention & control*; D006801:Humans; D007135:Immunoglobulin Variable Region / Q000737:chemistry; D051379:Mice; D008969:Molecular Sequence Data; D011993:Recombinant Fusion Proteins / Q000276:immunology; D014759:Viral Envelope Proteins / Q000276:immunology*
D000914:Antibodies, Viral; D007135:Immunoglobulin Variable Region; D011993:Recombinant Fusion Proteins; D014759:Viral Envelope Proteins